Theravectys SAS raised €7.48 million (US$9.4 million) in a third funding round to support what it claims will be the world's first trial of a therapeutic HIV vaccine based on a lentiviral vector. Read More
LONDON – A company based in Aberdeen, Scotland, that was founded and funded in Malaysia, with the aim of commercializing cancer vaccines discovered in Cuba, has announced the start of a pivotal Phase III trial of its lead product, BV-NSCLC-001. Read More
DUBLIN, Ireland – A greater emphasis on research collaborations between Irish academic scientists and international pharmaceutical firms and a doubling of patent licensing and spinout activities are two of the main action points in Science Foundation Ireland's newly published draft strategy document. Read More
LONDON – The UK BioIndustry Association (BIA) has drawn up a scheme to unlock the "patriotic potential" of the British public and enable them to invest in biotech and other technology start-ups through the creation of Citizen's Innovation Funds (CIF). Read More
Australian drug developer CBio Ltd. acquired privately held Inverseon Inc. in an all-stock deal, creating Invion Ltd., which will operate from offices in San Francisco and Brisbane. Read More
• Evolva Holding SA, of Reinach, Switzerland, reported further data for the first 32 patients enrolled in its Phase IIa study of EV-077, a reversible antagonist of isoprostanes and prostanoids, showing that, when given orally to Type II diabetes patients, the drug provided antiplatelet activity, reduced exercise-induced proteinuria and increased forearm blood flow. Read More
